logo-loader
viewFaron Pharmaceuticals Ltd

Faron Pharmaceuticals drug accepted to global pneumonia programme

The study will include patients suffering from coronavirus (COVID-19)

Faron Pharmaceuticals Ltd -

Faron Pharmaceuticals Oy (LON:FARN) (NASDAQFIRSTNORTH:FARON) said its drug Traumakine has been admitted to a large-scale global programme that will assess its potential in treating severe pneumonia, including patients with coronavirus (COVID-19).

Faron said its interferon beta-1 formulation will be delivered intravenously, which the company reckons offers the best “delivery route” for critically ill patients.

It will also be compared in the study with other treatments, including hydrocortisone medications. These steroid-based interventions, used in patients in respiratory distress, were seen as the potential root cause of a failed Faron phase III study of Traumakine.

"As this trial also has a hydrocortisone arm, it will provide a direct efficacy comparison between IFN beta-1a [Traumakine] and hydrocortisone, and will provide further prospective data on the concomitant use of these treatments, following previous observations that the use of overlapping corticosteroids are likely to have a deleterious effect on IFN beta-1,” said the drug developer’s chief executive, Dr Markku Jalkanen.

The Faron treatment has been accepted to the Randomised, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP).

Researchers plan to include 6,800 patients from study sites across Asia-Pacific, Europe and North America, excluding the US.

“The design of the REMAP-CAP trial will enable study subjects to be initiated onto investigational IV IFN beta-1a treatment relatively rapidly, on submission to intensive care, and before the development of ARDS [acute respiratory distress],” said CEO Jalkanen.

“Many of these patients have a severe viral infection and so are an optimal target cohort for the Traumakine-project and the investigation of its potential.”

Quick facts: Faron Pharmaceuticals Ltd

Price: 297.5 GBX

AIM:FARN
Market: AIM
Market Cap: £139.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Faron Pharma CEO details new US Traumakine study and updates on Clevegen...

Faron Pharmaceuticals' (LON:FARN) Dr Markku Jalkanen speaks to Proactive London's Andrew Scott following a successful virtual R&D day this week. He also reports on the continued progress for two of its clinical stage programmes, Clevegen and Traumakine, including the just-announced...

2 weeks, 5 days ago

2 min read